Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Boosted by NEOS Investment Management LLC

NEOS Investment Management LLC raised its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,761 shares of the company’s stock after purchasing an additional 6,878 shares during the period. NEOS Investment Management LLC owned about 0.09% of Day One Biopharmaceuticals worth $1,087,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. R Squared Ltd bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $31,000. Quest Partners LLC grew its holdings in shares of Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares during the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $143,000. KLP Kapitalforvaltning AS bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $150,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Day One Biopharmaceuticals during the 3rd quarter worth $174,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $8.07 on Friday. The stock has a market cap of $817.93 million, a price-to-earnings ratio of -7.83 and a beta of -1.38. Day One Biopharmaceuticals, Inc. has a 12 month low of $7.88 and a 12 month high of $18.07. The stock’s 50 day moving average price is $10.60 and its 200 day moving average price is $12.60.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. On average, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Wedbush reissued an “outperform” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Bank of America dropped their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. The Goldman Sachs Group reduced their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. cut their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Buy” and a consensus price target of $32.29.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is owned by insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.